BioCardia outlines design of CardiAMP HF II heart failure trial at HFSA 2026 meeting

Bitget2026/10/07 13:01

BioCardia flagged an upcoming HFSA 2026 poster detailing the design of its CardiAMP HF II heart-failure trial. Results have not been presented; the poster is scheduled for the October 9–12 meeting in Phoenix. The study is testing a high-dose autologous cell therapy in ischemic HFrEF patients still showing elevated heart-stress biomarkers on standard care. FDA has signaled the ongoing trial could be sufficient to support a potential US approval, sharpening the program’s regulatory path. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070900PRIMZONEFULLFEED9841218) on October 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%

Bitget•2026/11/09 08:14

Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high

Japan's spot electricity prices surged to multi-year highs over the weekend.

智通财经•2026/11/09 08:07

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01